文献速递肝病

肝硬化白蛋白治疗的争议

Controversies regarding albumin therapy in cirrhosis.
PubMed 文献 · Hepatology · 2023-08-07

综述指出,白蛋白由肝脏合成,在肝硬化中水平降低且质量下降,预测预后。大量放腹水后、自发性细菌性腹膜炎诊断时、急性肾损伤和肝肾综合征推荐输注白蛋白,但剂量和方案需优化,容量过载并发症日益明显。其他适应证证据阴性、有争议或不确定,白蛋白并非「一刀切」策略,适应证和患者选择至关重要。

要点

  • 大量放腹水后、自发性细菌性腹膜炎诊断时、急性肾损伤和肝肾综合征推荐输注白蛋白。
  • 白蛋白输注的剂量和方案需优化,容量过载并发症日益明显。
  • 其他适应证证据阴性、有争议或不确定,白蛋白并非「一刀切」策略。

核心结论

  • 白蛋白在肝硬化中的使用存在争议,适应证和患者选择至关重要,剂量和频率也影响成败。
  • 部分适应证证据不足,需等待随机对照试验结果。

研究设计与样本

  • 综述,讨论肝硬化白蛋白治疗的证据。

主要发现

  • 肝硬化中低白蛋白水平预测结局,晚期肝硬化白蛋白质量因高氧化应激和促炎状态而下降。
  • 大量放腹水后、自发性细菌性腹膜炎诊断时、急性肾损伤和肝肾综合征推荐输注白蛋白,但剂量和方案需优化。
  • 其他适应证如非自发性细菌性腹膜炎感染、低钠血症、肝性脑病、预防住院和门诊肝硬化患者不良结局的证据阴性、有争议或不确定。

关键数值与推荐

  • 大量放腹水后、自发性细菌性腹膜炎诊断时、急性肾损伤和肝肾综合征推荐输注白蛋白。
  • 白蛋白输注的剂量和方案需优化,容量过载并发症日益明显。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 其他适应证的证据阴性、有争议或不确定,需等待随机对照试验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Albumin is the most abundant protein in the human body and is synthetized exclusively by the liver. Therefore, serum albumin levels are reduced in acute and/or chronic liver disease. In cirrhosis, low levels of albumin predict the outcome. In advanced cirrhosis, the quality of albumin is decreased due to high oxidative stress and a proinflammatory state. Therefore, the administration of i.v. albumin would seem to be of pathophysiological relevance and benefit. Yet, the questions that remain are who, when, how much, and how often. While albumin infusion is recommended after large-volume paracentesis, at diagnosis of spontaneous bacterial peritonitis, in acute kidney injury, and in hepatorenal syndrome, the amount and schedule of albumin to be administered require refinement, particularly given complications related to volume overload that have become increasingly apparent. Other indications for albumin such as infections other than spontaneous bacterial peritonitis, hyponatremia, HE, prevention of poor outcomes in hospitalized, and in outpatients with cirrhosis are still debated. The results of studies in these settings are either negative, controversial, or inconclusive. This sheds some doubts regarding the use of albumin as a "one size fits all" strategy. The indication and patient selection are crucial and not always intuitive. The amount and frequency also seem to play a role in the success or failure of albumin. This review will critically discuss the evidence and underline areas where there are indications for albumin use and others where evidence is still insufficient and will have to await the development/results of randomized controlled trials.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Trebicka J, Garcia-Tsao G. Controversies regarding albumin therapy in cirrhosis. Hepatology. 2023. PMID: 37540192. doi:10.1097/HEP.0000000000000521

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。